Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Monday, March 17th. Analysts expect Abeona Therapeutics to post earnings of ($0.35) per share and revenue of $0.10 million for the quarter.
Abeona Therapeutics Stock Down 2.6 %
Abeona Therapeutics stock opened at $5.16 on Monday. Abeona Therapeutics has a fifty-two week low of $3.05 and a fifty-two week high of $8.87. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. The company has a market capitalization of $224.31 million, a P/E ratio of -1.92 and a beta of 1.79. The stock has a 50-day simple moving average of $5.56 and a 200-day simple moving average of $5.85.
Analyst Ratings Changes
Several equities analysts recently issued reports on ABEO shares. StockNews.com cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 22nd. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Abeona Therapeutics in a research report on Wednesday, February 19th. Finally, Oppenheimer started coverage on Abeona Therapeutics in a research report on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 price target on the stock. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $17.50.
About Abeona Therapeutics
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Featured Stories
- Five stocks we like better than Abeona Therapeutics
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Institutional Investors Bet $1B on These 4 Stocks—Should You?
- Quiet Period Expirations Explained
- One Must-Buy Stock and One to Avoid as Tariffs Shake the Market
- Upcoming IPO Stock Lockup Period, Explained
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
